Natixis Advisors LLC Boosts Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Natixis Advisors LLC grew its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 10.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,030,069 shares of the medical equipment provider's stock after purchasing an additional 184,264 shares during the quarter. Natixis Advisors LLC owned approximately 0.14% of Boston Scientific worth $181,326,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Boston Scientific by 4.4% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 4,119,399 shares of the medical equipment provider's stock valued at $345,205,000 after buying an additional 173,034 shares during the period. Mechanics Bank Trust Department purchased a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $415,000. Highland Capital Management LLC bought a new position in Boston Scientific in the fourth quarter worth approximately $4,887,000. Covenant Asset Management LLC purchased a new position in Boston Scientific during the 4th quarter worth $3,405,000. Finally, Brookstone Capital Management raised its position in Boston Scientific by 23.7% during the 4th quarter. Brookstone Capital Management now owns 105,860 shares of the medical equipment provider's stock valued at $9,455,000 after purchasing an additional 20,307 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

BSX has been the topic of a number of recent research reports. Wells Fargo & Company increased their price target on Boston Scientific from $100.00 to $118.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. StockNews.com cut shares of Boston Scientific from a "buy" rating to a "hold" rating in a report on Saturday, March 8th. Citigroup boosted their price target on shares of Boston Scientific from $107.00 to $122.00 and gave the company a "buy" rating in a report on Thursday, February 6th. Morgan Stanley increased their price objective on shares of Boston Scientific from $100.00 to $120.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. Finally, Truist Financial upped their target price on Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a report on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $108.91.

Remove Ads

Insider Buying and Selling at Boston Scientific

In other news, EVP John Bradley Sorenson sold 4,119 shares of the company's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total value of $370,792.38. Following the sale, the executive vice president now directly owns 35,319 shares of the company's stock, valued at $3,179,416.38. This represents a 10.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Daniel J. Brennan sold 15,087 shares of the firm's stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $105.07, for a total transaction of $1,585,191.09. Following the transaction, the chief financial officer now directly owns 241,451 shares of the company's stock, valued at approximately $25,369,256.57. This trade represents a 5.88 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 137,302 shares of company stock worth $14,319,269. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Performance

NYSE:BSX traded up $0.03 during trading hours on Tuesday, hitting $98.93. 2,326,825 shares of the company were exchanged, compared to its average volume of 5,731,092. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. Boston Scientific Co. has a 52-week low of $66.16 and a 52-week high of $107.17. The stock has a market capitalization of $146.00 billion, a price-to-earnings ratio of 79.14, a PEG ratio of 2.79 and a beta of 0.77. The company's 50 day moving average price is $101.21 and its 200-day moving average price is $91.97.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. As a group, research analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.